Quantcast

Latest Crizotinib Stories

2014-08-18 23:02:59

The anti-cancer drug Xalkori® is being investigated by the ECOG-ACRIN Cancer Research Group in E4512, a phase III trial. Philadelphia, PA (PRWEB) August 18, 2014 People diagnosed with early-stage non-squamous non-small cell lung cancer whose tumors have an altered ALK gene now have the opportunity to participate in a new phase III clinical trial, ECOG-ACRIN announced today. The trial will determine if Xalkori® (generic name crizotinib, an ALK-inhibitor), when used after...

2014-08-18 16:28:13

WASHINGTON, Aug. 18, 2014 /PRNewswire-USNewswire/ -- Lung Cancer Alliance (LCA) President & CEO, Laurie Fenton Ambrose praised the National Cancer Institute's (NCI) new trial, launched today, that will focus on the prevention of recurrence in two specific types of lung cancers when they are caught at early stage and surgically removed. "This trial demonstrates the power of CT screening to open new research windows on critical problems, such as recurrence, that have eluded...

2014-06-10 12:30:30

LONDON, June 10, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Non-small cell lung cancer: Game changing immunotherapies to revolutionise treatment - KOL Insighthttp://www.reportbuyer.com/pharma_healthcare/diseases/non_small_cell_lung_cancer_game_changing_immunotherapies_revolutionise_treatment_kol_insight.html Change is coming to the NSCLC treatment algorithm--and it's coming soon. Revolutionary new immunotherapies, more personalised treatment choices...

2014-06-03 11:22:42

University of Colorado Denver A study presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2014 reports the results of a first-in-human, phase 1 dose escalation trial of crizotinib (XALKORI) in 14 patients with advanced, MET-amplified non-small cell lung cancer (NCT00585195). In 2011, the drug crizotinib earned accelerated approval by the US FDA to target the subset of advanced non-small cell lung cancers caused by rearrangements of the anaplastic lymphoma...

2014-06-02 22:55:01

University of Colorado Denver A University of Colorado Cancer Center study presented at the 50th Annual Meeting of the American Society for Clinical Oncology (ASCO) draws a line from mutation of the gene NTRK1, to its role as an oncogene in non-small cell lung cancer, to treatment that targets this mutation. The current study reports the prevalence of the NTRK1 mutation in an unselected population of 450 lung cancer samples, with >1% percent of patients testing positive. This and other...

2014-06-02 16:26:19

- Ceritinib achieved overall response rate of 58.5%, with a median progression-free survival of 8.2 months1 EAST HANOVER, N.J., June 2, 2014 /PRNewswire/ -- Novartis today announced data showing Zykadia((TM) )(ceritinib, previously known as LDK378) shrank tumors in patients with anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC), including those who had received previous treatment with an ALK inhibitor as well as patients receiving one for the first time. Results...

2014-05-01 20:24:06

Ceritinib (brand name Zykadia(TM)) will be used for the treatment of patients with anaplastic lymphoma kinase-positive (ALK+) metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib (brand name Xalkori(TM)) WASHINGTON, May 1, 2014 /PRNewswire-USNewswire/ -- LUNGevity Foundation applauds the FDA approval of Zykadia(TM) for the subset of anaplastic lymphoma kinase-positive (ALK+) patients with advanced cases of non-small cell lung cancer who have...

2014-04-29 16:32:08

- Zykadia (ceritinib) demonstrated an overall response rate of 54.6% in patients with ALK+ metastatic NSCLC who have no other treatment option[1] EAST HANOVER, N.J., April 29, 2014 /PRNewswire/ -- Novartis announced today that the US Food and Drug Administration (FDA) has approved Zykadia(TM) (ceritinib, previously known as LDK378) for the treatment of patients with anaplastic lymphoma kinase-positive (ALK+) metastatic non-small cell lung cancer (NSCLC) who have progressed on or are...

2014-03-26 16:25:46

- Data showed investigational treatment LDK378 (ceritinib) also achieved a median progression-free survival of seven months EAST HANOVER, N.J., March 26, 2014 /PRNewswire/ -- Novartis today announced that The New England Journal of Medicine (NEJM) published clinical trial results showing the investigational compound LDK378 (ceritinib) achieved an overall response rate (ORR, including complete response [CR] and partial response [PR]) of 58% and a median progression-free survival (PFS) of seven...

2014-02-25 14:34:50

Results Support Need for Combined Testing The findings of a recent study indicate that routine testing with both fluorescent in situ hybridization (FISH) and immunohistochemistry (IHC) may enhance the detection of ALK-positive non-small cell lung cancer (NSCLC). Accurate determination of ALK-positive tumors is necessary to identify patients with advanced NSCLC who are most likely to benefit from targeted therapy with an ALK inhibitor. The discovery of ALK rearrangement in about 1% to 7%...


Word of the Day
cacodemon
  • An evil spirit; a devil.
  • A nightmare.
  • In astrology, the twelfth house of a scheme or figure of the heavens: so called from its signifying dreadful things, such as secret enemies, great losses, imprisonment, etc.
'Cacodemon' comes from a Greek term meaning 'evil genius.'
Related